Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections

John Christenson, W. Manford Gooch, John N. Herrod, Elise Swenson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cefprozil is a new oral semi-synthetic cephalosporin with broad antibacterial spectrum and prolonged serum elimination half-life. In vitro, cefprozil demonstrates excellent activity against common urinary tract pathogens such as Escherichia coli and Klebsiella pneumoniae. Cefprozil, 500 mg once a day, was compared to cefaclor, 250 mg three times a day, in an open, randomized, comparative, clinical trial for the treatment of acute, uncomplicated, urinary tract infection. One hundred and two adult patients were eligible for safety evaluation; four patients were excluded due to side-effects (abdominal discomfort, nausea and vomiting). Ninety-eight patients were eligible for evaluation of efficacy. Clinical and bacteriological responses were comparable for both antibiotics. Leucopenia, nausea, and vaginal yeast infections were slightly more common in the cefprozil group. Cefprozil, 500 mg once daily, appears to be an appropriate alternative for the treatment of acute, uncomplicated urinary tract infections.

Original languageEnglish (US)
Pages (from-to)581-586
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume28
Issue number4
DOIs
StatePublished - Oct 1991
Externally publishedYes

Fingerprint

Cefaclor
Pathogens
Antibiotics
Urinary Tract Infections
Acute
Yeast
Escherichia coli
Nausea
Infection
Efficacy
Safety
Vomiting
Evaluation
Clinical Trials
Escherichia Coli
Elimination
Therapeutics
Leukopenia
Klebsiella pneumoniae
Cephalosporins

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)
  • Pharmacology
  • Microbiology

Cite this

Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections. / Christenson, John; Gooch, W. Manford; Herrod, John N.; Swenson, Elise.

In: Journal of Antimicrobial Chemotherapy, Vol. 28, No. 4, 10.1991, p. 581-586.

Research output: Contribution to journalArticle

@article{e7eb87b31ccb4559a654ef7d00951eb4,
title = "Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections",
abstract = "Cefprozil is a new oral semi-synthetic cephalosporin with broad antibacterial spectrum and prolonged serum elimination half-life. In vitro, cefprozil demonstrates excellent activity against common urinary tract pathogens such as Escherichia coli and Klebsiella pneumoniae. Cefprozil, 500 mg once a day, was compared to cefaclor, 250 mg three times a day, in an open, randomized, comparative, clinical trial for the treatment of acute, uncomplicated, urinary tract infection. One hundred and two adult patients were eligible for safety evaluation; four patients were excluded due to side-effects (abdominal discomfort, nausea and vomiting). Ninety-eight patients were eligible for evaluation of efficacy. Clinical and bacteriological responses were comparable for both antibiotics. Leucopenia, nausea, and vaginal yeast infections were slightly more common in the cefprozil group. Cefprozil, 500 mg once daily, appears to be an appropriate alternative for the treatment of acute, uncomplicated urinary tract infections.",
author = "John Christenson and Gooch, {W. Manford} and Herrod, {John N.} and Elise Swenson",
year = "1991",
month = "10",
doi = "10.1093/jac/28.4.581",
language = "English (US)",
volume = "28",
pages = "581--586",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Comparative efficacy and safety of cefprozil and cefaclor in the treatment of acute uncomplicated urinary tract infections

AU - Christenson, John

AU - Gooch, W. Manford

AU - Herrod, John N.

AU - Swenson, Elise

PY - 1991/10

Y1 - 1991/10

N2 - Cefprozil is a new oral semi-synthetic cephalosporin with broad antibacterial spectrum and prolonged serum elimination half-life. In vitro, cefprozil demonstrates excellent activity against common urinary tract pathogens such as Escherichia coli and Klebsiella pneumoniae. Cefprozil, 500 mg once a day, was compared to cefaclor, 250 mg three times a day, in an open, randomized, comparative, clinical trial for the treatment of acute, uncomplicated, urinary tract infection. One hundred and two adult patients were eligible for safety evaluation; four patients were excluded due to side-effects (abdominal discomfort, nausea and vomiting). Ninety-eight patients were eligible for evaluation of efficacy. Clinical and bacteriological responses were comparable for both antibiotics. Leucopenia, nausea, and vaginal yeast infections were slightly more common in the cefprozil group. Cefprozil, 500 mg once daily, appears to be an appropriate alternative for the treatment of acute, uncomplicated urinary tract infections.

AB - Cefprozil is a new oral semi-synthetic cephalosporin with broad antibacterial spectrum and prolonged serum elimination half-life. In vitro, cefprozil demonstrates excellent activity against common urinary tract pathogens such as Escherichia coli and Klebsiella pneumoniae. Cefprozil, 500 mg once a day, was compared to cefaclor, 250 mg three times a day, in an open, randomized, comparative, clinical trial for the treatment of acute, uncomplicated, urinary tract infection. One hundred and two adult patients were eligible for safety evaluation; four patients were excluded due to side-effects (abdominal discomfort, nausea and vomiting). Ninety-eight patients were eligible for evaluation of efficacy. Clinical and bacteriological responses were comparable for both antibiotics. Leucopenia, nausea, and vaginal yeast infections were slightly more common in the cefprozil group. Cefprozil, 500 mg once daily, appears to be an appropriate alternative for the treatment of acute, uncomplicated urinary tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0026014884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026014884&partnerID=8YFLogxK

U2 - 10.1093/jac/28.4.581

DO - 10.1093/jac/28.4.581

M3 - Article

VL - 28

SP - 581

EP - 586

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 4

ER -